Evidence map›Paper›PMID 32925768›Full record

ArticleMedicine2020

Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma.

Xianwu Xia, Yaqi Wang, Jianjun Yuan, Wenjie Sun, Jinjin Jiang, Chang Liu, Qunling Zhang, Xuejun Ma

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Prognostic value of the pre-treatment SUVmax ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  2. Article
  3. Review
  4. Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (Quantitative imaging in medicine and surgery · 2024
    Article
  5. PreoperativeCancers · 2024
    Article
  6. Article
  7. BaselineDiagnostics (Basel, Switzerland) · 2023
    Article
  8. Enhancement ofDiagnostics (Basel, Switzerland) · 2022
    Article
  9. Clinical Perspectives forMetabolites · 2022
    Review
  10. The Role of Pre-therapeuticFrontiers in medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xianwu XiaDepartment of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, Taizhou, Zhejiang.
Yaqi WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center.
Jianjun YuanDepartment of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, Taizhou, Zhejiang.
Wenjie SunDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center.
Jinjin JiangDepartment of Oncology, Shanghai Medical College, Fudan University.
Chang LiuDepartment of Oncology, Shanghai Medical College, Fudan University.
Qunling ZhangDepartment of Oncology, Shanghai Medical College, Fudan University.
Xuejun MaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center.ORCID 0000-0001-9936-4194
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNTaizhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the prognostic value of the baseline SUVmax of F-FDG PET-CT in extranodal natural killer/T-cell lymphoma (NKTCL) patients.From January 2010 to December 2015, 141 extranodal NKTCL patients with staging F-FDG PET-CT scan were divided into two group based on SUVmax cutoff value obtained from operating characteristic (ROC) curves. All the patients received radiotherapy, chemotherapy or chemoradiation. Survival analysis was performed on the basis of SUVmax.The median baseline SUVmax of the tumors was 11.67 (range 2.6-34.6). The ROC curves showed that the optimal cutoff of the baseline SUVmax was 9.65. The patients were divided into two groups: low SUV group (SUVmax < 9.65) and high SUV group (SUVmax ≥ 9.65). Patients in high SUV group were more likely to have invasive disease outside the nasal cavity (P < .001), poorer ECOG scores (P = .012) and higher LDH levels (P = .034). The univariate survival analyses indicated that high SUVmax was a poor prognostic factor for overall survival (OS, P = .038), progression free survival (PFS, P = .006) and distant relapse free survival (DRFS, P = .001), but not for local recurrence free survival (LRFS, P > .05). These results were consistent with that of the survival analyses using the Kaplan-Meier method. The multivariate survival analyses showed that the baseline SUVmax was no longer a prognostic factor for OS (HR 1.99, 95% CI 0.81-4.88, P = .135), but it still indicated worse PFS (HR 2.6, 95% CI 1.24-5.46, P = .012) and DRFS (HR 4.58, 95% CI 1.83-11.46, P = .001) independent of other variables.For extranodal NKTCL patients, a higher baseline SUVmax of F-FDG PET-CT was associated with more aggressive clinical features. An SUVmax ≥ 9.65 was an independent poor prognostic factor for DRFS and PFS. Thus, the baseline SUVmax may be a valuable tool to help identify patients with a high risk of disease progression.

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRadiopharmaceuticalsAgedFemaleHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedPrognosisRetrospective StudiesROC CurveSurvival AnalysisSurvival RateFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID32925768
PMCPMC7489640
OpenAlexW3085721473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.